PMID- 30159874
OWN - NLM
STAT- MEDLINE
DCOM- 20190301
LR  - 20211204
IS  - 1528-1167 (Electronic)
IS  - 0013-9580 (Linking)
VI  - 59 Suppl 2
DP  - 2018 Oct
TI  - Efficacy and safety of perampanel oral loading in postanoxic super-refractory 
      status epilepticus: A pilot study.
PG  - 243-248
LID - 10.1111/epi.14492 [doi]
AB  - Refractory nonconvulsive status epilepticus (NCSE) occurs in 10%-30% of patients 
      following resuscitation after cardiac arrest. Both the optimal treatment and 
      prognosis of postanoxic status epilepticus remain uncertain. We analyzed acute 
      electroencephalographic changes, neurological outcome at 3 months, and adverse 
      effects in consecutive postanoxic patients with super-refractory NCSE treated 
      with add-on oral loading of perampanel. Eight postanoxic patients with 
      super-refractory NCSE were treated with perampanel (dose range = 6-12 mg). All 
      patients had continuous electroencephalographic monitoring showing definite 
      generalized NCSE and favorable multimodal prognostic indicators (presence of 
      brainstem reflexes, presence of bilateral N20 responses, absence of periodic 
      discharges/generalized epileptic periodic discharges). In six patients (75%), 
      status epilepticus resolved within 72 hours after administration of perampanel, 
      without changing the comedication. Neurological outcomes at 3 months were return 
      to normal or minimal disability in four patients (50%). A mild cholestatic liver 
      injury, which required no specific treatment, was observed in five patients 
      (62.5%). Perampanel 6-12 mg oral loading appeared to be an effective option in 
      selected patients with postanoxic super-refractory NCSE with good prognostic 
      indicators. In this patient population, our safety data indicate a risk of 
      cholestasis.
CI  - Wiley Periodicals, Inc. (c) 2018 International League Against Epilepsy.
FAU - Beretta, Simone
AU  - Beretta S
AD  - Epilepsy Center, San Gerardo Hospital Monza, University of Milano Bicocca, Monza, 
      Italy.
FAU - Padovano, Giada
AU  - Padovano G
AD  - Epilepsy Center, San Gerardo Hospital Monza, University of Milano Bicocca, Monza, 
      Italy.
FAU - Stabile, Andrea
AU  - Stabile A
AD  - Epilepsy Center, San Gerardo Hospital Monza, University of Milano Bicocca, Monza, 
      Italy.
FAU - Coppo, Anna
AU  - Coppo A
AD  - Department of Intensive Care, San Gerardo Hospital Monza, Monza, Italy.
FAU - Bogliun, Graziella
AU  - Bogliun G
AD  - Epilepsy Center, San Gerardo Hospital Monza, University of Milano Bicocca, Monza, 
      Italy.
FAU - Avalli, Leonello
AU  - Avalli L
AD  - Department of Intensive Care, San Gerardo Hospital Monza, Monza, Italy.
FAU - Ferrarese, Carlo
AU  - Ferrarese C
AD  - Epilepsy Center, San Gerardo Hospital Monza, University of Milano Bicocca, Monza, 
      Italy.
LA  - eng
PT  - Journal Article
DEP - 20180829
PL  - United States
TA  - Epilepsia
JT  - Epilepsia
JID - 2983306R
RN  - 0 (Anticonvulsants)
RN  - 0 (Nitriles)
RN  - 0 (Pyridones)
RN  - H821664NPK (perampanel)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aged
MH  - Anticonvulsants/*therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Electroencephalography
MH  - Female
MH  - Heart Arrest/*complications
MH  - Humans
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - Nitriles
MH  - Pilot Projects
MH  - Pyridones/*therapeutic use
MH  - Retrospective Studies
MH  - Status Epilepticus/diagnostic imaging/*drug therapy/*etiology
MH  - Treatment Outcome
OTO - NOTNLM
OT  - perampanel
OT  - postanoxic
OT  - prognosis
OT  - refractory status epilepticus
EDAT- 2018/08/31 06:00
MHDA- 2019/03/02 06:00
CRDT- 2018/08/31 06:00
PHST- 2017/11/24 00:00 [accepted]
PHST- 2018/08/31 06:00 [pubmed]
PHST- 2019/03/02 06:00 [medline]
PHST- 2018/08/31 06:00 [entrez]
AID - 10.1111/epi.14492 [doi]
PST - ppublish
SO  - Epilepsia. 2018 Oct;59 Suppl 2:243-248. doi: 10.1111/epi.14492. Epub 2018 Aug 29.